R&G PharmaStudies Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 23.94%

R&G PharmaStudies Co. Ltd. A (301333) has an Asset Resilience Ratio of 23.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of R&G PharmaStudies Co. Ltd. A to measure the company's free cash flow as a share of total liabilities.

Liquid Assets

CN¥574.90 Million

≈ $84.13 Million USD Cash + Short-term Investments

Total Assets

CN¥2.40 Billion

≈ $351.41 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2023–2025)

This chart shows how R&G PharmaStudies Co. Ltd. A's Asset Resilience Ratio has changed over time. See 301333 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down R&G PharmaStudies Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see R&G PharmaStudies Co. Ltd. A market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥574.90 Million	23.94%
Total Liquid Assets	CN¥574.90 Million	23.94%

Asset Resilience Insights

Good Liquidity Position: R&G PharmaStudies Co. Ltd. A maintains a healthy 23.94% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

R&G PharmaStudies Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare R&G PharmaStudies Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for R&G PharmaStudies Co. Ltd. A (2023–2025)

The table below shows the annual Asset Resilience Ratio data for R&G PharmaStudies Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	25.84%	CN¥620.12 Million ≈ $90.74 Million	CN¥2.40 Billion ≈ $351.14 Million	-4.45pp
2024-12-31	30.29%	CN¥707.61 Million ≈ $103.55 Million	CN¥2.34 Billion ≈ $341.86 Million	-4.06pp
2023-12-31	34.35%	CN¥712.39 Million ≈ $104.24 Million	CN¥2.07 Billion ≈ $303.46 Million	--

pp = percentage points

About R&G PharmaStudies Co. Ltd. A

SHE:301333 China Biotechnology

Market Cap

$664.95 Million

CN¥4.54 Billion CNY

Market Cap Rank

#10979 Global

#3082 in China

Share Price

CN¥47.05

Change (1 day)

+0.41%

52-Week Range

CN¥44.03 - CN¥91.20

All Time High

CN¥91.20